The early prevention of asthma in atopic children (EPAAC) study. A multi-country, double blind, placebo (PLC) controlled, randomized, parallel group trial: evaluation of the efficacy and safety of levocetirizine (LCTZ) (5 mg/mL oral drops -0.125 mg/kg b.w. b.i.d. [twice daily]) administered for 18 months in preventing the onset of asthma in 12 to 24 months old children who suffer from atopic dermatitis and are sensitized to grass pollen and / or house dust mite allergens.

Trial Profile

The early prevention of asthma in atopic children (EPAAC) study. A multi-country, double blind, placebo (PLC) controlled, randomized, parallel group trial: evaluation of the efficacy and safety of levocetirizine (LCTZ) (5 mg/mL oral drops -0.125 mg/kg b.w. b.i.d. [twice daily]) administered for 18 months in preventing the onset of asthma in 12 to 24 months old children who suffer from atopic dermatitis and are sensitized to grass pollen and / or house dust mite allergens.

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Oct 2014

At a glance

  • Drugs Levocetirizine (Primary)
  • Indications Asthma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms EPAAC
  • Sponsors UCB
  • Most Recent Events

    • 01 Sep 2007 Tolerability results have been published.
    • 22 Jul 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top